New Analyses Suggests Early Covid Treatment Benefits Were Valid
I was rebutted in the US Senate on November 19, 2020, by Dr. Ashish Jha who was at the Brown School of Public Health at the time and later became the White House Coronavirus Coordinator
In response to my presentation of the McCullough Protocol for the early treatment of high-risk patients with acute COVID-19, he told America that his patients and doctors would only accept results from large, prospective randomized trials.
By the way, the only COVID-19 products with such trials were mRNA vaccines.
Now a new analysis from Salcher-Konrad et al has found for drug therapies, that randomized trials yield a slightly more conservative estimate of effect size, specifically 19 percent lower.
That means for observational, comparative studies with large effect sizes done in the field, the results are likely to be valid.
For example, through 2020 Procter et al reported their results with early multidrug therapy for acute COVID-19: 87.6 and 74.9 percent reductions in hospitalization and death, respectively.
That means at worst, the real effects were 70.9 and 60.7 percent — huge public health benefits were thrown aside by the soon-to-be vaccine promoter Jha.
If we have learned anything through the pandemic, we cannot wait for large randomized trials that will take years to complete and likely just confirm what doctors are observing in the field.
Clinical judgment, empiricism, and observational data have crucial roles to play in future pandemics.
See more here substack.com
Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.